相关实验视频

Updated: Jan 8, 2026

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

TLR7通过PI3K/AKT/mTOR途径和免疫微环境重塑来调节质母细胞瘤的进展

Liwen Guo¹, Xianlei Zhou², Zhi Zhang³

¹College of Life Sciences, North China University of Science and Technology, Tangshan, China.

Irish journal of medical science

|December 13, 2025

概括

托尔类受体7 (TLR7) 的过度表达通过抑制细胞生长和促进抗瘤免疫反应来抑制质母细胞瘤 (GBM) 的进展. 这表明TLR7是攻击性脑瘤的潜在治疗标.

科学领域:

神经瘤学神经瘤学
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

质母细胞瘤 (GBM) 是一种具有高度攻击性的脑瘤,治疗选择有限.
托尔类受体7 (TLR7),是天生的免疫系统的一部分,在GBM病变发生过程中没有明确的作用.
确定新的治疗点对于改善GBM治疗结果至关重要.

研究的目的:

调查托尔类受体7 (TLR7) 过度表达对质母细胞瘤 (GBM) 进展的影响.
阐明潜在的分子机制,包括信号通路和免疫微环境调制.
评估针对GBM中的TLR7的治疗潜力.

主要方法:

在人类质母细胞瘤细胞系 (U87,U251) 中使用等离子体转染物过度表达TLR7.
使用CCK-8,殖民地形成,Transwell和伤口愈合试验评估细胞增殖,迁移和入侵.
通过使用qRT-PCR和细胞因子分析,分析PI3K/AKT/mTOR通路通过西部斑点和巨极化激活.

主要成果:

通过qRT-PCR证实TLR7的成功过度表达.
过度表达TLR7显著抑制了GBM细胞的增殖,殖民地形成,迁移和入侵.
TLR7抑制PI3K/AKT/mTOR信号通路,并促进M1巨细胞的两极分化,增强抗瘤免疫力.

结论:

通过PI3K/AKT/mTOR途径抑制细胞进展,TLR7作为质母细胞瘤抑制剂.
通过调节巨细胞极化,TLR7促进了抗瘤免疫微环境.
在质母细胞瘤治疗中,TLR7是一个有前途的治疗点.

关键词:

在GBMGBMGBMGBMGBM 巨细胞的两极分化在PI3K/AKT/mTOR信号通路中.在TLR7中,治疗目标是治疗的目标.

更多相关视频

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion

Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion

Published on: October 20, 2016

相关概念视频

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...